CXCR4 inhibitors: Tumor vasculature and therapeutic challenges

Recent Patents on Anti-Cancer Drug Discovery

Volumn 7, Issue 3, 2012, Pages 251-264

  de Nigris, Filomena ^a   Schiano, Concetta ^a   Infante, Teresa ^b   Napoli, Claudio ^a,b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b IRCCS SDN   (Italy)

Author keywords

Angiogenesis; Cancer; CXCL12; CXCR4; Metastasis; Vasculogenesis

Indexed keywords

ALB 408; ANTINEOPLASTIC AGENT; BKT 140; BMS 936564; CCX 2066; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CHEMOKINE RECEPTOR CXCR7; CTCE 9908; GRANULOCYTE COLONY STIMULATING FACTOR; MDX 1338; MICRORNA; MICRORNA 146A; MONOCLONAL ANTIBODY; MSX 122; N [1,4,8,11 TETRAAZACYCLOTETRADECANYL 1,4 PHENYLENEBIS(METHYLENE)] 2 (AMINOMETHYL)PYRIDINE; NOX A12; PACLITAXEL; PLERIXAFOR; POL 6236; POL 6326; QUIZARTINIB; RAPAMYCIN; SMALL INTERFERING RNA; SORAFENIB; STROMAL CELL DERIVED FACTOR 1; TG 0054; TN 14003; TZ 14011; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; WZ 811;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADJUVANT THERAPY; ANTIANGIOGENIC ACTIVITY; BREAST CANCER; CHRONIC LYMPHATIC LEUKEMIA; DRUG ABSORPTION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG TARGETING; GLIOBLASTOMA; HUMAN; LEUKEMIA; LUNG METASTASIS; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; METASTASIS POTENTIAL; MULTIPLE MYELOMA; MYELOID LEUKEMIA; NONHODGKIN LYMPHOMA; NONHUMAN; OSTEOSARCOMA; PATENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RECEPTOR BLOCKING; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; STEM CELL MOBILIZATION; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD VESSELS; CHEMOKINE CXCL12; ENDOTHELIUM, VASCULAR; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, CXCR4;

EID: 84867563401     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489212801820039     Document Type: Review

References (131)

1. Folkman J. Angiogenesis: An organizing principle for drug discovery? Nat Rev Drug Discov 2007; 6: 273-86.
2. Napoli C, Giordano A, Casamassimi A, Pentimalli F, Ignarro LJ, de Nigris F. Directed in vivo angiogenesis assay and the study of systemic neoangiogenesis in cancer. Int J Cancer 2011; 128: 1505-8.
3. Li Calzi S, Neu MB, Shaw LC, Kielczewski JL, Moldovan NI, Grant MB. EPCs and pathological angiogenesis: When good cells go bad. Microvasc Res 2010; 79: 207-16.
4. Salvatore P, Pagliarulo C, Colicchio R, Napoli C. CXCR4-CXCL12-dependent inflammatory network and endothelial progenitors. Curr Med Chem 2010; 17: 3019-29.
5. Spring H, Schuler T, Arnold B, Hammerling GJ, Ganss R. Chemokines direct endothelial progenitors into tumor neovessels. Proc Natl Acad Sci USA 2005; 102: 18111-6.
6. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006; 3: 24-40.
7. Veeravagu A, Hsu AR, Cai W, Hou LC, Tse VC, Chen X. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy. Recent Pat Anticancer Drug Discov 2007; 2: 59-71.
8. Singh S, Sadanandam A, Singh RK. Chemokines in tumor angiogenesis and metastasis. Cancer Metastasis Rev 2007; 26: 453-67.
9. Busillo JM, Benovic JL. Regulation of CXCR4 signalling. Biochim Biophys Acta 2007; 1768: 952-63.
10. Levoye A, Balabanian K, Baleux F, Bachelerie F, Lagane B. CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. Blood 2009; 113: 6085-93.
11. Doitsidou M, Reichman-Fried M, Stebler J, Köprunner M, Dörries J, Meyer D, et al. Guidance of primordial germ cell migration by the chemokine SDF-1. Cell 2002; 111: 647-9.
12. Mirshahi F, Pourtau J, Li H, Muraine M, Trochon V, Legrand E, et al. SDF-1 activity on microvascular endothelial cells: Consequences on angiogenesis in vitro and in vivo models. Thromb Res 2000; 99: 587-94.
13. Ratajczak MZ, Zuba-Surma E, Kucia M, Reca R, Wojakowski W, Ratajczak J. The pleiotropic effects of the SDF-1-CXCR4 axis in organogenesis, regeneration and tumorigenesis. Leukemia 2006; 20: 1915-24.
14. Christopher MJ, Liu F, Hilton MJ, Long F, Link DC. Suppression of CXCL12 production by bone marrow osteoblasts is a common and critical pathway for cytokine-induced mobilisation. Blood 2009; 114: 1331-9.
15. Lapidot T, Kollet O. The essential roles of the chemokine SDF-1 and its receptor CXCR4 in human stem cell homing and repopulation of transplanted immune-deficient NOD/SCID and NOD/SCID/ B2m (null) mice. Leukemia 2002; 16: 1992-2003.
16. Nie Y, Han YC, Zou YR. CXCR4 is required for the quiescence of primitive hematopoietic cells. J Exp Med 2008; 205: 777-83.
17. Wright DE, Bowman EP, Wagers AJ, Butcher EC, Weissman IL. Hematopoietic stem cells are uniquely selective in their migratory response to chemokines. J Exp Med 2002; 195: 1145-54.
18. Petit I, Jin D, Rafii S. The SDF-1-CXCR4 signalling pathway: A molecular hub modulating neo-angiogenesis. Trends Immunol 2007; 28: 299-307.
19. Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 2010; 16: 2927-31.
20. Sun X, Cheng G, Hao M, Zheng J, Zhou X, Zhang J, et al. CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev 2010; 29: 709-22.
21. Orimo A, Weinberg RA. Stromal fibroblasts in cancer: A novel tumor-promoting cell type. Cell Cycle 2006; 5: 1597-601.
22. Kojima Y, Acar A, Eaton EN, Mellody KT, Scheel C, Ben-Porath I, et al. Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signalling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc Natl Acad Sci USA 2010; 107: 20009-14.
23. Darash-Yahana M, Pikarsky E, Abramovitch R, Zeira E, Pal B, Karplus R, et al. Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis. FASEB J 2004; 18: 1240-42.
24. Miao Z, Luker KE, Summers BC, Berahovich R, Bhojani MS, Rehemtulla A, et al. CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc Natl Acad Sci USA 2007; 104: 15735-40.
25. Hinton CV, Avraham S, Avraham HK. Role of the CXCR4/CXCL12 signaling axis in breast cancer metastasis to the brain. Clin Exp Metastasis 2010; 27: 97-105.
26. Du R, Lu KV, Petritsch C, Liu P, Ganss R, Passegué E, et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008; 13: 206-20.
27. +hemangiocytes. Nat Med 2006; 12: 557-67.
28. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2006; 121: 335-48.
29. Phillips RJ, Mestas J, Gharaee-Kermani M, Burdick MD, Sica A, Belperio JA, et al. Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signalling pathway and activation of hypoxia inducible factor-1alpha. J Biol Chem 2005; 280: 22473-81.
30. Strasser GA, Kaminker JS, Tessier-Lavigne M. Microarray analysis of retinal endothelial tip cells identifies CXCR4 as a mediator of tip cell morphology and branching. Blood 2010; 115: 5102-10.
31. Cabioglu N, Summy J, Miller C, Parikh NU, Sahin AA, Tuzlali S, et al. CXCL-12/stromal cell-derived factor-1alpha transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation. Cancer Res 2005; 65: 6493-7.
32. Wang J, Sun Y, Song W, Nor JE, Wang CY, Taichman RS. Diverse signaling pathways through the SDF-1/CXCR4 chemokine axis in prostate cancer cell lines leads to altered patterns of cytokine secretion and angiogenesis. Cell Signal 2005; 17: 1578-92.
33. de Nigris F, Crudele V, Giovane A, Casamassimi A, Giordano A, Garban HJ, et al. CXCR4/YY1 inhibition impairs VEGF network and angiogenesis during malignancy. Proc Natl Acad Sci USA 2010; 107: 14484-9.
34. de Nigris F, Botti C, de Chiara A, Rossiello R, Apice G, Fazioli F, et al. Expression of transcription factor Yin Yang 1 in human osteosarcoma. Eur J Cancer 2006; 42: 2420-4.
35. Kryczek I, Lange A, Mottram P, Alvarez X, Cheng P, Hogan M, et al. CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res 2005; 65: 465-72.
36. Hiratsuka S, Duda DG, Huang Y, Goel S, Sugiyama T, Nagasawa T, et al. C-X-C receptor type 4 promotes metastasis by activating p38 mitogen-activated protein kinase in myeloid differentiationantigen (Gr-1) positive cells. Proc Natl Acad Sci USA 2011; 108: 302-7.
37. Matsusue R, Kubo H, Hisamori S, Okoshi K, Takagi H, Hida K, et al. Hepatic stellate cells promote liver metastasis of colon cancer cells by the action of SDF-1/CXCR4 axis. Ann Surg Oncol 2009; 16: 2645-53.
38. Hirbe AC, Morgan EA, Weilbaecher KN. The CXCR4/SDF-1 chemokine axis: A potential therapeutic target for bone metastases? Curr Pharm Des 2010; 16: 1284-90.
39. Alphonso A, Alahari SK. Stromal cells and integrins: Conforming to the needs of the tumor microenvironment. Neoplasia 2009; 11: 1264-71.
40. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007; 1: 313-23.
41. de Nigris F, Rossiello R, Schiano C, Arra C, Williams-Ignarro S, Barbieri A, et al. Deletion of Yin Yang 1 protein in osteosarcoma cells on cell invasion and CXCR4/angiogenesis and metastasis. Cancer Res 2008; 68: 1797-808.
42. Kozin SV, Kamoun W, Huang Y, Dawson MR, Jain RK, Duda DG. Recruitment of myeloid but not endothelial precursor cells facilitates tumor re-growth after local irradiation. Cancer Res 2010; 70: 5679-85.
43. Kioi M, Vogel H, Schultz G, Hoffman RM, Harsh GR, Brown JM. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest 2010; 120: 694-705.
44. Redjal N, Chan JA, Segal RA, Kung AL. CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas. Clin Cancer Res 2006; 12: 6765-71.
45. Duda DG, Kozin SV, Kirkpatrick ND, Xu L, Fukumura D, Jain RK. CXCL12 (SDF1{alpha})-CXCR4/CXCR7 pathway inhibition: An emerging sensitizer for anticancer therapies? Clin Cancer Res 2011; 17: 2074-80.
46. Scala S, Ottaiano A, Ascierto PA, Cavalli M, Simeone E, Giuliano P, et al. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res 2005; 11: 1835-41.
47. Li Y, Flores R, Yu A, Okcu MF, Murray J, Chintagumpala M, et al. Elevated expression of CXC chemokines in pediatric osteosarcoma patients. Cancer 2011; 117: 207-17.
48. Bian XW, Yang SX, Chen JH, Ping YF, Zhou XD, Wang QL, et al. Preferential expression of chemokine receptor CXCR4 by highly malignant human gliomas and its association with poor patient survival. Neurosurgery 2007; 61: 570-8.
49. Wang SC, Lin JK, Wang HS, Yang SH, Li AF, Chang SC. Nuclear expression of CXCR4 is associated with advanced colorectal cancer. Int J Colorectal Dis 2010; 25: 1185-91.
50. Franco R, Botti G, Mascolo M, Loquercio G, Liguori G, Ilardi G, et al. CXCR4-CXCL12 and VEGF correlate to uveal melanoma progression. Front Biosci 2010; 2: 13-21.
51. Franco R, Cantile M, Scala S, Catalano E, Cerrone M, Scognamiglio G, et al. Histomorphologic parameters and CXCR4 mRNA and protein expression in sentinel node melanoma metastasis are correlated to clinical outcome. Cancer Biol Ther 2010; 9: 423-9.
52. Damon LE, Damon LE. Pilot study to relate clinical outcome in pancreatic carcinoma and angiogenic plasma factors/circulating mature/progenitor endothelial cells: Preliminary results. Expert Rev Hematol 2009; 2: 717-33.
53. D'Alterio C, Cindolo L, Portella L, Polimeno M, Consales C, Riccio A, et al. Differential role of CD133 and CXCR4 in renal cell carcinoma. Cell Cycle 2010; 9: 4492-500.
54. Colmone A, Amorim M, Pontier AL, Wang S, Jablonski E, Sipkins DA. Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science 2008; 322: 1861-5.
55. Xu L, Duda DG, di Tomaso E, Ancukiewicz M, Chung DC, Lauwers GY, et al. Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. Cancer Res 2009; 69: 7905-10.
56. Zhu AX, Sahani DV, Duda DG, Di Tomaso E, Ancukiewicz M, Catalano OA, et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: A phase II study. J Clin Oncol 2009; 27: 3027-35.
57. Yoon SS, Duda DG, Karl DL, Kim TM, Kambadakone AR, Chen YL, et al. Phase II study of neoadjuvant bevacizumab and radiotherapy for resectable soft tissue sarcomas. Int J Radiat Oncol Biol Phys 2011; 81: 1081-90.
58. Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, et al. Phase II study of cediranib, an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 2010; 28: 2817-22.
59. Liang Z, Yoon Y, Votaw J, Goodman MM, Williams L, Shim H. Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res 2005; 65: 967-71.
60. Kuhne, M., Brams, P., Tanamachi, D.M., Korman, A. Cardarelli, J.M. Human antibodies that bind CXCR4 and uses thereof. WO2008060367 (2008).
61. Klinguer-Amour, C. Use of an anti-CXCR4 antibody for treating cancer. WO2008142303 (2008).
62. Peled, A., Beider, K. CCL20-specific antibodies for cancer therapy. WO2009156994 (2009).
63. Dickerson, C.T., Marquis, D.M., Obungu, V., Peng, S.B., Vaillancourt, P.E. Anti-CXCR4 antibodies. WO2009140124 (2009).
64. Klinguer-Hamour, C., Grenier-Caussanel, V. Anti CXCR4 antibodies and their use for the treatment of cancer. WO2010037831 (2010).
65. Kavlie, A., Kiprijanov, S.M. Antibodies. WO2011098762 (2011).
66. Dewilde, M., Gonzalez Pajuelo, M., Vanlandschoot, P., Cromie, K., Pattyn, E., Serruys, B., Stortelers, C., Strubbe, B. Immunoglobulin single variable domain directed against human CXCR4. WO2011083140 (2011).
67. Schotte, P., Brige, A., Dewilde, M., Stals, H., Strubbe, B. Improved immunoglobulin single variable domains and constructs there of directed against CXCR4. WO2011161266 (2011).
68. Klinguer-Hamour, C., Jouhanneaud, A., Grenier-Caussanel, V. Humanized anti CXCR4 antibodies for the treatment of cancer. WO2011121040 (2011).
69. De Clercq E. Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobi) and potential of other CXCR4 antagonists as stem cell mobilizers. Pharmacol Ther 2010; 128: 509-18.
70. nd, et al. Effects of AMD3100 on transmigration and survival of acute myelogenous leukemia cells. Leuk Res 2007; 31: 1553-63.
71. Shim, H., Liang, Z., Umbreit, J., Taichman, R., Goodmann, M. CXCR4 antagonists and methods of their use. WO2004087068 (2004).
72. Shim, H., Liotta, D.C., Snyder, J.P., Zhan, W., Liang, Z. CXCR4 antagonists for the treatment of medical disorders. WO2006074428 (2006).
73. Bridger, G.P., Louis, M. Methods to enhance chemotherapy. WO2007022523 (2007).
74. Liotta, D.C., Snyder, J.P., Zhan, W. CXCR4 antagonists including diazine and triazine structures for the treatment of medical disorders. WO2008008854 (2008).
75. Bridger, G., Pelus, L.M. Combination therapy. WO2008017025 (2008) & WO2008019371 (2008).
76. Hu, Y., Siders, W., Kaplan, J. Methods and compositions for treating hematological malignancies. WO2010088398 (2010).
77. Alt, E.U., Arlinghaus, R.B., Coleman, M.E. Prophylaxis against cancer metastasis. WO2011014863 (2011).
78. Kochetkova, M., McColl, S., Kleinig, M.J., Coley, A.M. Chemokine receptor heteromultimers, compounds that bind thereto and uses thereof. WO2011123903 (2011).
79. Azab AK, Runnels JM, Pitsillides C, Moreau AS, Azab F, Leleu X, et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 2009; 113: 4341-51.
80. Williams SA, Harata-Lee Y, Comerford I, Anderson RL, Smyth MJ, McColl SR. Multiple functions of CXCL12 in a syngeneic model of breast cancer. Mol Cancer 2010; 17: 250.
81. Kioi M, Vogel H, Schultz G, Hoffman RM, Harsh GR, Brown JM. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest 2010; 120: 694-705.
82. Kim M, Koh YJ, Kim KE, Koh BI, Nam DH, Alitalo K, et al. CXCR4 signalling regulates metastasis of chemoresistant melanoma cells by a lymphatic metastatic niche. Cancer Res 2010; 70: 10411-21.
83. Voloshin T, Gingis-Velitski S, Bril R, Benayoun L, Munster M, Milsom C, et al. G-CSF supplementation with chemotherapy can promote revascularization and subsequent tumor regrowth: Prevention by a CXCR4 antagonist. Blood 2011; 118: 3426-35.
84. Jin L, Tabe Y, Konoplev S, Xu Y, Leysath CE, Lu H, et al. CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells. Mol Cancer Ther 2007; 7: 48-58.
85. Zeng Z, Shi YX, Samudio IJ, Wang RY, Ling X, Frolova O, et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 2009; 113: 6215-24.
86. Melikian, A., Wright, J.J., Krasinski, A., Hu, C., Novack, A. Substituted quinolones and methods of use. WO2007059108 (2007).
87. Epstein RJ. The CXCL12-CXCR4 chemotactic pathway as a target of adjuvant breast cancer therapies. Nat Rev Cancer 2004; 4: 901-9.
88. Natchus M, Arrendale R, Donald L. MSX-122, an orally available small molecule CXCR4 antagonist, promotes leukocytosis in monkeys at doses that were well tolerated in a 28 day toxicology study. AACR Annual Meeting-2009, Proceedings 2008 GA, USA (2008) 49.
89. Zhan W, Liang Z, Zhu A, Kurtkaya S, Shim H, Snyder JP, et al. Discovery of small molecule CXCR4 antagonists. J Med Chem 2007; 50: 5655-64.
90. Berkenstam, A., Rehnmark, S., Witt, M.R., Lorimer, K., Watt, S. Crystalline forms of genistein. WO2010068861 (2010).
91. Stefely JA, Palchaudhuri R, Miller PA, Peterson RJ, Moraski GC, Hergenrother PJ, et al. N (1-benzyl-1H-1,2,3-triazol-4-yl)methyl) arylamide as a new scaffold that provides rapid access to antimicrotubule agents: Synthesis and evaluation of antiproliferative activity against select cancer cell lines. J Med Chem 2010; 53: 3389-95.
92. Masuda M, Nakashima H, Ueda T, Naba H, Ikoma R, Otaka A, et al. A novel anti-HIV synthetic peptide, T-22 ([Tyr5,12, Lys7]-polyphemusin II). Biochem Biophys Res Commun 1992; 189: 845-50.
93. Rosen C.A., Haseltine W.A. Albumin fusion proteins. WO01079444 (2001), WO01079480 (2001) & WO201079480 (2010).
94. Arakaki R, Tamamura H, Premanathan M, Kanbara K, Ramanan S, Mochizuki K, et al. T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure. J Virol 1999; 73: 1719-23.
95. Juarez J, Bradstock KF, Gottlieb DJ, Bendall LJ. Effects of inhibitors of the chemokine receptor CXCR4 on acute lymphoblastic leukemia cells in vitro. Leukemia 2003; 17: 1294-300.
96. Yoon Y, Liang Z, Zhang X, Choe M, Zhu A, Cho HT, et al. CXC chemokine receptor-4 antagonist blocks both growth of primary tumor and metastasis of head and neck cancer in xenograft mouse models. Cancer Res 2007; 67: 7518-24.
97. Liang Z, Wu T, Lou H, Yu X, Taichman RS, Lau SK, et al. Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4. Cancer Res 2004; 64: 4302-8.
98. Mori T, Doi R, Koizumi M, Toyoda E, Ito D, Kami K, et al. CXCR4 antagonist inhibits stromal cell-derived factor 1-induced migration and invasion of human pancreatic cancer. Mol Cancer Ther 2004; 3: 29-37.
99. Yan L, Anderson GM, DeWitte M, Nakada MT. Therapeutic potential of cytokine and chemokine antagonists in cancer therapy. Eur J Cancer 2006; 42: 793-802.
100. Yanaka, M., Yamazaki, T., Bannai, K., Hirose, K. CXCR4 antagonistic drugs comprising nitrogen-containing compound. WO02094261 (2002).
101. Kohn, W.D., Peng, S.B., Yan, L.Z. Cyclic peptide CXCR4 antagonists. WO2008150689 (2008).
102. Demarco, S.J., Mukherjee, R., Moehle, K., Robinson, J.A., Henze, H., Romagnoli, B., Obrecht, D., Gombert, F., Ludin, C., Vrijbloed, J.W. Template-fixed peptidomimetics. WO2008104090 (2008).
103. Remus, J.T., Lemercier, G. Beta-hairpin peptidomimetics. WO2011066869 (2011).
104. Obrecht, D., Gombert, F.O., Lederer, A., Romagnoli, B., Bisang, C. Beta-hairpin peptidomimetics having CXCR4 antagonizing activity. WO2010127704 (2010).
105. Gombert, F.O., Obrecht, D., Lederer, A., Romagnoli, B. Templatefixed beta-hairpin peptidomimetics with cxcr4 antagonizing activity. WO2010060479 (2010).
106. Forssmann, W.G., Kirchhoff, F., Munch, J., Standker, L. A CXC chemokine receptor 4 (CXCR4) antagonistic polypeptide. WO2009004054 (2009).
107. Poznansky, M.C., Jaafar, H.S.F., Coleman, D.V., Leblanc, P. Methods for detecting and treating cancer. WO2010037042 (2010).
108. Looby, R.J., Tchernychev, B. CXCR4 receptor compounds. WO2011106703 (2011).
109. Stern, P.L., Saha, V. Prognostic, screening and treatment methods and agents for treatment of metastasis and inflammation using T54 oncofoetal glycoprotein. WO2011048369 (2011).
110. Lapidot, T., Kalinkovich, A., Fridkin, M. Short beta-defensinderived peptides. WO2010092571 (2010).
111. Amodeo, P., Vitale, R., De Luca, S., Scala, S., Castiello, G., Siani, A. Cyclic peptides binding CXCR4 receptor and relative medical and diagnostic uses. WO2011092575 (2011).
112. Quay, S.C., Mcswiggen, J., Vaish, N.K., Ahmadian, M. Nucleic acid compounds for inhibiting CXC gene expression and uses thereof. WO2008109520 (2008).
113. Liang Z, Wu H, Reddy S, Zhu A, Wang S, Blevins D, et al. Blockade of invasion and metastasis of breast cancer cells via targeting CXCR4 with an artificial microRNA. Biochem Biophys Res Commun 2007; 363: 542-6.
114. Peschle, C., Labbaye, C. Antisense RNA targeting CXCR4. WO2009100955 (2009).
115. Fujii, N. Novel polypeptides and anti HIV drugs containing the same. WO02020561 (2002).
116. Shim, H., Liotta, D.C., Zhu, A., Goodman, M. CXCR4 antagonists for imaging of cancer and inflammatory disorders. WO2011094389 (2011).
117. Purschke, W., Jarosch, F., Eulberg, D., Klussmann, S., Buchner, K., Maasch, C., Dinse, N. SDF-1 binding nucleic acids and the use thereof. WO2009019007 (2007).
118. Van Der Westhuizen, J.H., Eljaleel, A.E.M.N., Bonnet, S.L., Wilhelm-Mouton, A. Aminoalkyl substituted chalcones and analogues and derivatives thereof. WO2011151789 (2011).
119. Marasco, W.A., Sui, J., Xu, C. Antibodies against CXCR4 and methods of use thereof. WO2006089141 (2006).
120. Kim SY, Lee CH, Midura BV, Yeung C, Mendoza A, Hong SH, et al. Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin Exp Metastasis 2008; 25: 201-11.
121. Porvasnik S, Sakamoto N, Kusmartsev S, Eruslanov E, Kim WJ, Cao W, et al. Effects of CXCR4 antagonist CTCE-9908 on prostate tumor growth. Prostate 2009; 69: 1460-9.
122. Huang EH, Singh B, Cristofanilli M, Gelovani J, Wei C, Vincent L, et al. A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J Surg Res 2009; 155: 231-6.
123. Magnani, J.L., Sarkar, A.K. Heterobifunctional inhibitors of eselectins and CXCR4 chemokine receptors. WO2010126888 (2010).
124. Chen, X., Fan, P., Gleason, M.M., Jaen, J.C., Li, L., Mcmahon, J.P., Powers, J., Zeng, Y., Zhang, P. Modulators of CXCR7. WO2010054006 (2010).
125. Alsayed Y, Ngo H, Runnels J, Leleu X, Singha UK, Pitsillides CM, et al. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood 2007; 109: 2708-17.
126. Nervi B, Ramirez P, Rettig MP, Uy GL, Holt MS, Ritchey JK, et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood 2009; 113: 6206-14.
127. Di Persio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colonystimulating factor compared with placebo plus granulocyte colonystimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009; 27: 4767-73.
128. Steinberg M, Silva M. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma. Clin Ther 2010; 32: 8218-43.
129. Beider K, Begin M, Abraham M, Wald H, Weiss ID, Wald O, et al. A CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth. Exp Hematol 2011; 39: 282-92.
130. Müller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50-6.
131. Zlotnik A. New insights on the role of CXCR4 in cancer metastasis. J Pathol 2008; 215: 211-3.